TrialCardiovascular diabetology2020

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.

Wataru Shimizu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.